.Planet Health Association. Being overweight and over weight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Disease Risk Aspect Cooperation. Worldwide fads in under a healthy weight and also weight problems from 1990 to 2022: a pooled analysis of 3663 population-representative researches with 222 thousand little ones, teens, and also grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google Scholaru00c2.International Concern Ailment Collaborators. Global, regional, as well as national worry of diabetic issues from 1990 to 2021, along with projections of frequency to 2050: a systematic evaluation for the Global Problem of Illness Research Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google.com Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Planet Kidney Day Guiding Board. Excessive weight as well as renal disease: hidden outcomes of the wide-ranging. Kidney Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
A step-by-step assessment and also meta-analysis recommends being overweight forecasts onset of severe kidney disease in the basic population. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google Scholaru00c2.Jiang, Z. et cetera. Obesity and chronic kidney ailment.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Venue, J. E., carry out Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Obesity, renal disorder as well as hypertension: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Renal Disease: Improving Global End Results CKD Workplace Team.
KDIGO 2024 Clinical Practice Guideline for the evaluation and also control of chronic kidney disease. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Renal Condition: Improving Global Results Diabetes Work Group. KDIGO 2022 Scientific Process Tip for diabetic issues control in persistent renal health condition. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et al.
Very early change in albuminuria along with canagliflozin predicts kidney and also cardio results: an article hoc analysis coming from the CREDENCE trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et al. Proteinuria, a target for renoprotection in individuals with style 2 diabetic nephropathy: sessions coming from RENAAL.
Kidney Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. et cetera. Is a decrease in albuminuria associated with renal and also heart protection?
An article hoc study of the height test. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic kidney ailment: an assessment of their kidney and heart security. Am.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 and the renal: coming from physiology to pharmacology and end results in diabetes mellitus.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide and heart outcomes in patients along with kind 2 diabetes. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et al. Semaglutide as well as cardio outcomes in obesity without diabetes mellitus. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et al.
Effects of semaglutide on chronic kidney disease in people along with kind 2 diabetes. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Colhoun, H. M. et cetera.
Long-lasting renal results of semaglutide in being overweight as well as heart attack in the SELECT trial. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Impacts of semaglutide on albuminuria and also kidney feature in folks along with overweight or even weight problems with or even without kind 2 diabetic issues: prolegomenous study from the action 1, 2, and also 3 trials.
Diabetic issues Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Medicine Man, A. M.
et al. Result of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal results in clients along with kind 2 diabetes: pooled evaluation of SUSTAIN 6 and LEADER. Circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et al.
Impact of semaglutide on renal functionality throughout various amounts of guideline HbA1c, blood pressure, physical body weight as well as albuminuria in SUSTAIN 6 and also PIONEER 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus insulin glargine in clients along with type 2 diabetes mellitus and also moderate-to-severe severe kidney condition (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetic Issues Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et al.
Modification in albuminuria as a surrogate endpoint for progress of renal illness: a meta-analysis of treatment results in randomised clinical tests. Lancet Diabetes Mellitus Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et al. Results of semaglutide with as well as without coupled with SGLT2 inhibitor use in attendees with type 2 diabetic issues and also severe kidney ailment in the circulation test. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, renal and also protection outcomes along with GLP-1 receptor agonists alone and in blend with SGLT2 inhibitors in type 2 diabetes mellitus: an organized customer review and meta-analysis.
Circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et al. Efficacy as well as protection of SGLT2 inhibitors with and also without glucagon-like peptide 1 receptor agonists: a SMART-C joint meta-analysis of randomised controlled trials. Lancet Diabetic Issues Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Effects of tirzepatide versus insulin glargine on kidney results in type 2 diabetes mellitus in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, period 3 trial.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et cetera. Body system body weight as well as eGFR throughout dulaglutide treatment in kind 2 diabetic issues and moderate-to-severe constant kidney disease (AWARD-7).
Diabetic issues Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et al. Results of tirzepatide versus the hormone insulin glargine on cystatin c-based renal feature: a SURPASS-4 blog post hoc review. Diabetic issues Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetes Mellitus Treatment (American Diabetic issues Affiliation, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Results of bariatric surgery on renal functionality in obese clients: a methodical review and meta evaluation.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The impacts of bariatric surgical procedure on kidney results: an organized examine and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et al. The measured glomerular purification fee (mGFR) before and 6 months after bariatric surgical treatment: a fly research study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et cetera. Adiponectin decreases glomerular endothelial glycocalyx disturbance and also rejuvenates glomerular barricade functionality in a computer mouse design of style 2 diabetic issues. Diabetes 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration pertaining to diabetes mellitus as well as excessive weight in individual ailment. World J.
Diabetes 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Assessing albuminuria in individuals along with weight problems: challenges of the urinary system albumin-creatinine proportion. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in adults with obese or being overweight.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Levey, A.
S. et cetera. A more precise strategy to determine glomerular purification percentage coming from serum creatinine: a brand-new forecast equation.
Adjustment of Diet Regimen in Renal Health Condition Study Hall. Ann. Intern.
Medication. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS procedure for iohexol resolution in individual EDTA and also lithium-heparin blood, individual pee as well as in goat- as well as swine EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et cetera.
Efficacy and also safety and security of aldosterone synthase hangup with and also without empagliflozin for constant kidney condition: a randomised, handled, period 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et al. Efficiency of a novel inhibitor of general adhesion protein-1 in decreasing albuminuria in clients with diabetic kidney ailment (ALBUM): a randomised, placebo-controlled, period 2 test. Lancet Diabetes Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Zibotentan in mixture along with dapagliflozin compared with dapagliflozin in patients along with chronic renal condition (ZENITH-CKD): a multicentre, randomised, active-controlled, stage 2b, professional trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Result of avenciguat on albuminuria in people with CKD: two randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in individuals with IgA nephropathy: a prespecified meantime evaluation due to a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.